Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases.
Stock is 

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Cantor Fitzgerald
Alethia Young
Cowen
Marc Frahm
Goldman Sachs
Salveen Richter
H.C. Wainright
Mike King
JP Morgan
Anupam Rama
Leerink Partners
Andrew Berens M.D.
Oppenheimer & Co.
Mark Breidenbach Ph.D.
Raymond James
Danielle Brill
RBC Capital Markets
Kennen MacKay

Agios Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Agios Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Agios Pharmaceuticals, Inc. or its management. Agios Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Resources
FAQs
Email Alerts
Publications